The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Summary. Hepatitis C virus (HCV) infection is a major cause of liver‐related morbidity and mortality among thalassaemic patients. In order to analyse the effect of the current anti‐HCV treatment in this subset of HCV‐infected patients, we conducted a systematic review with meta‐analysis of the available literature. The outcome was sustained viral response. Both comparative [odds ratio (OR)] and non‐comparative...
Summary. Worldwide, 50–70 million subjects are infected with an hepatitis C virus (HCV) genotype 2, 3, 4, 5 or 6. In these patients, the combination of PEG‐INF‐α and ribavirin remains the currently approved standard‐of‐care treatment. The identification of different potential therapeutic targets in the HCV life cycle has led to the development of both direct antiviral agents (DAAs) and reagents targeting...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.